Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study

BACKGROUND: Talazoparib, a poly(ADP-ribose) polymerase enzyme inhibitor, is approved for the treatment of patients with germline BRCA1/2 (gBRCA1/2)-mutated HER2-negative advanced breast cancer. This two-part study, a recently published dose-escalation part followed by the dose-expansion part reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotani, Haruru, Masuda, Norikazu, Yamashita, Toshinari, Naito, Yoichi, Taira, Tetsuhiko, Inoue, Kenichi, Takahashi, Masato, Yonemori, Kan, Toyoizumi, Shigeyuki, Mori, Yuko, Nagasawa, Takashi, Hori, Natsuki, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587945/
https://www.ncbi.nlm.nih.gov/pubmed/35907135
http://dx.doi.org/10.1007/s12282-022-01390-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587945/
https://www.ncbi.nlm.nih.gov/pubmed/35907135
http://dx.doi.org/10.1007/s12282-022-01390-w

Ejemplares similares